UPDATE: PiperJaffray Reiterates Overweight On Bausch Health Companies, Raises Target To $39 Based On Firm's Read Of Key Segments Of The Business '(e.g., dermatology; gastroenterology, namely Xifaxan and Trulance)'

Benzinga · 12/30/2019 15:28